"Windsor Dermatology is the home of the Psoriasis Treatment Center of New Jersey, the state’s first complete facility for advanced psoriasis clinical research. Since 1985 our Medical Director, Dr. Bagel, has been at the forefront of psoriasis patient care, treatment and clinical research, making the Center and Windsor Dermatology one of the most respected clinical settings in America for psoriasis treatment. Although there is currently no cure for psoriasis, many effective treatments are available. Treatments for Psoriasis are much better than what we had 10 years ago. However, there can be substantial variation between individuals in the effectiveness of specific psoriasis therapies."

During the past decade, Psoriasis Treatment Center of Central New Jersey conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 29 clinical trials were completed, i.e. on average, 65.9% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 22 clinical trials were completed. i.e. 95.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Psoriasis Treatment Center of Central New Jersey" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Psoriasis Treatment Center of Central New Jersey" with 9 trials sponsored, "LEO Pharma" with 7 trials sponsored, "Amgen" with 5 trials sponsored and "Boehringer Ingelheim" with 5 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Psoriasis Treatment Center of Central New Jersey" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "LEO Pharma" with 2 trials as a collaborator, "Athenex, Inc." with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Psoriasis Treatment Center of Central New Jersey" are "Psoriasis" (21 trials), "Plaque Psoriasis" (9 trials), "Atopic Dermatitis" (7 trials), "Psoriasis Vulgaris" (6 trials) and "Chronic Plaque Psoriasis" (2 trials). Many other conditions were trialed in "Psoriasis Treatment Center of Central New Jersey" in a lesser frequency.

Most popular intervention types in "Psoriasis Treatment Center of Central New Jersey" are "Drug" (48 trials), "Other" (5 trials), "Biological" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Lebrikizumab" (4 trials), "Apremilast" (3 trials), "Ixekizumab" (3 trials) and "Mirikizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Psoriasis Treatment Center of Central New Jersey" are 52 trials for "All" genders.

Currently, there are NaN active trials in "Psoriasis Treatment Center of Central New Jersey". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Psoriasis Treatment Center of Central New Jersey, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Psoriasis Treatment Center of Central New Jersey, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 1 trials that are defined as “Not Applicable".